English Visit Patient Site >100 Scientific Articles Published Results from multiple randomized clinical trials of the Zephyr® Valve have demonstrated clinically meaningful benefits in lung function, exercise capacity, and quality of life (QoL).1-5 4 RCTs published using Zephyr Valve and Chartis® to preselect patients1-5 Published in the New England Journal of Medicine, The Lancet, and The American Journal of Respiratory and Critical Care Medicine1-5,16 Statistically significant and clinically meaningful improvements compared to standard of care in multiple trials1-4 Treatment success seen in a broad range of primary and secondary endpoints1-5 Consistent Clinical Findings Across Four Randomized Controlled Trials RCT Design Sample size & follow-up period Procedural Success (TLVR%) Difference Zephyr Valve vs. Control Groups (ITT) LUNG FUNCTION (FEV1%) MCID = 10%-15% EXCERCISE CAPACITY (6MWD) MCID = 26 M LIBERATE1 2:1 Randomization Heterogeneous only Multicenter n=190 12 months 84% 18.0% p<0.001 p=0.002 TRANSFORM2 2:1 Randomization Heterogeneous only Multicenter n=97 6 months 90% 29.3% p<0.001 79 m p<0.001 IMPACT3 1:1 Randomization Homogeneous only Multicenter n=93 6 months* 89% 16.3% p<0.001 28 m p=0.016 STELVIO4,5 1:1 Randomization Heterogeneous & Homogeneous Single Center n=68 6 months 88% 17.8% p=0.001 74 m p<0.001 *Data on file at PMX (not in publication) **Completed cases, all other values listed are ITT population T Difference between valve and control groups FEV1 Percent Change from Baseline to 12 Months (p<0.001) Δ=17.96 Zephyr Valve(n=128) 12 Months -10 -5 0 5 10 15 20 25 Percent Change (%) Published in The American Journal of Respiratory and Critical Care Medicine1 The benefits are comparable to those seen with LVRS (lung volume reduction surgery) but with a reduction in post-procedure morbidity.” Multicenter, multinational, randomized controlled trial Results out to 12 months Heterogeneous emphysema with little to no collateral ventilation Clinically meaningful and statistically significant benefits over current standard of care medical therapy Improvements in: Lung function Exercise tolerance Dyspnea Quality of life Learn More Published in The American Journal of Respiratory and Critical Care Medicine2 Benefits are in line with those seen with LVRS (lung volume reduction surgery), and the consistent trial results, potential reduction in post-procedure morbidity, and reversibility of the procedure position Zephyr treatment as a viable treatment option in those who remain symptomatic on maximal medical therapy.” Multicenter, multinational, randomized controlled trial Heterogeneous emphysema with little or no collateral ventilation Clinically meaningful and statistically significant benefits over current standard of care medical therapy Improvements in: Lung function Exercise tolerance Dyspnea Quality of life Learn More FEV1 Percent Change from Baseline to 6 Months (p<0.001) Δ=29.3% Zephyr Valve(n=65) 6 Months -20 -10 0 10 20 30 Percent Change (%) FEV1 Percent Change From Baseline To 6 Months (p<0.001) Δ=16.27% Zephyr Valve(n=43) 6 Months -10 -5 0 5 10 15 20 25 Percent Change (%) Published in The American Journal of Respiratory and Critical Care Medicine3 EBV therapy in selected patients with homogeneous emphysema without collateral ventilation results in clinically meaningful benefits of improved lung function, exercise tolerance, and quality of life. Given the very limited treatment options available for this patient population, EBV therapy should be considered in these patients.” Prospective randomized controlled trial Homogeneous emphysema with little or no collateral ventilation Clinically meaningful benefits in: Lung function Exercise tolerance Quality of life View Webinar Learn More Published in The New England Journal of Medicine4 Endobronchial valve treatment in patients with emphysema and a proven absence of interlobar collateral ventilation provided a measurable clinical benefit, with significantly improved lung function, exercise capacity, and quality of life as compared with usual care.” Prospective randomized controlled trial First randomized study to use Chartis® to pre-select candidates Emphysema with little or no collateral ventilation Statistically and clinically greater improvements than the control group for: Pulmonary function (FEV1 and FVC) Exercise capacity Quality of life One-year follow-up published in The American Journal of Respiratory and Critical Care Medicine5 Learn More FEV1 Percent Change From Baseline To 6 Months (p=0.001) Δ=17.8% Zephyr Valve(n=34) 6 Months -10 0 10 20 30 40 Percent Change (%) International Guidance Documents Include Endobronchial Valve Treatment as an Option for Emphysema Patients Multiple independent networks have concluded that with proper patient selection, the Zephyr Valve procedure should be considered in the treatment of severe emphysema. The quality of evidence for treatment with endobronchial valves has been graded “A” by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).10 The United Kingdom’s National Institute for Health and Care Excellence (NICE) has included this treatment as part of standard measures for COPD and recommended all qualifying patients be evaluated for eligibility.11,34 Patient Treatment Preference A detailed survey of 294 severe emphysema patients evaluated how they balance potential risks and benefits. The study concluded that patients with severe emphysema value access to an interventional treatment that offers benefits above and beyond their current medical management, despite the risks associated with these treatments.8 Learn More Need More? View Full Bibliography Download Clinical Summaries *Intent to Treat ©2020 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners. | Site Designed by The Deciding Factor, Inc. P0980EN_A February 2019 Resources About Pulmonx Management Team Company History For Patients For Physicians Contact Us Privacy Policy EU and UK Privacy Policy Terms of Use Sitemap Prescriptive Information Follow Us In order to provide you with an optimal website experience, we use cookies. By clicking "Accept" you agree to the use of cookies. Further information can be found in our privacy policy.Accept